A | HUMAN NECESSITIES | ||||
HEALTH; LIFE-SAVING; AMUSEMENT | |||||
A61 | MEDICAL OR VETERINARY SCIENCE; HYGIENE | ||||
D | A61K | PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J 3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) | |||
Note(s) [2006.01]
| |||||
D | A61K 6/00 | Preparations for dentistry [2020.01] | |||
D | A61K 8/00 | Cosmetics or similar toiletry preparations [2006.01] | |||
D | A61K 9/00 | Medicinal preparations characterised by special physical form [2006.01] | |||
A61K 9/02 | • Suppositories; Bougies; Bases for suppositories or bougies (apparatus for making A61J 3/08; devices for introducing into the body A61M 31/00) [2006.01] | ||||
A61K 9/06 | • | ||||
A61K 9/08 | • Solutions [2006.01] | ||||
A61K 9/10 | • Dispersions; Emulsions [2006.01] | ||||
A61K 9/107 | • • Emulsions [2006.01] | ||||
A61K 9/113 | • • • | ||||
A61K 9/12 | • • Aerosols; Foams [2006.01] | ||||
A61K 9/127 | • • Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant [2025.01] | ||||
Warning: In this group and its new subgroup, reclassification of PCT Minimum Documentation published before January 1, 2025, is not yet completed! See also the Revision Concordance List (RCL) for more details. | |||||
A61K 9/1271 | • • • Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates A61K 47/69) [2025.01] | ||||
A61K 9/1272 | • • • • comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents A61K 47/54) [2025.01] | ||||
A61K 9/1273 | • • • • Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances [2025.01] | ||||
A61K 9/1274 | • • • Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases [2025.01] | ||||
A61K 9/1275 | • • • Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof [2025.01] | ||||
A61K 9/1276 | • • • Globules of milk; Constituents thereof [2025.01] | ||||
A61K 9/1277 | • • • Preparation processes; Proliposomes [2025.01] | ||||
A61K 9/1278 | • • • • Post-loading, e.g. by ion or pH gradient [2025.01] | ||||
A61K 9/133 | (transferred to A61K 9/127-A61K 9/1273, A61K 9/1277-A61K 9/1278) | ||||
A61K 9/14 | • | ||||
A61K 9/16 | • • Agglomerates; Granulates; Microbeadlets [2006.01] | ||||
A61K 9/18 | • • Adsorbates [2006.01] | ||||
A61K 9/19 | • • lyophilised [2006.01] | ||||
A61K 9/20 | • Pills, lozenges or tablets [2006.01] | ||||
A61K 9/22 | • • Sustained or differential release type [2006.01] | ||||
A61K 9/24 | • • • Layered or laminated unitary dosage forms [2006.01] | ||||
A61K 9/26 | • • • Discrete particles in supporting matrix [2006.01] | ||||
A61K 9/28 | • • Dragees; Coated pills or tablets [2006.01] | ||||
A61K 9/30 | • • • Organic coatings [2006.01] | ||||
A61K 9/32 | • • • • containing solid synthetic polymers [2006.01] | ||||
A61K 9/34 | • • • • containing natural gums or resins [2006.01] | ||||
A61K 9/36 | • • • • | ||||
A61K 9/38 | • • • • containing proteins or derivatives thereof [2006.01] | ||||
A61K 9/40 | • • • • • Gelatin containing [2006.01] | ||||
A61K 9/42 | • • • • containing waxes, higher fatty acids, higher fatty alcohols, or derivatives thereof, e.g. chocolate [2006.01] | ||||
A61K 9/44 | • • printed, embossed, grooved, or perforated [2006.01] | ||||
A61K 9/46 | • • effervescent [2006.01] | ||||
A61K 9/48 | • Preparations in capsules, e.g. of gelatin, of chocolate [2006.01] | ||||
A61K 9/50 | • • | ||||
A61K 9/51 | • • • Nanocapsules [2006.01] | ||||
A61K 9/52 | • • Sustained or differential release type [2006.01] | ||||
A61K 9/54 | • • • | ||||
A61K 9/56 | • • • • Organic coatings [2006.01] | ||||
A61K 9/58 | • • • • • containing solid synthetic polymers [2006.01] | ||||
A61K 9/60 | • • • • • containing natural gums or resins [2006.01] | ||||
A61K 9/62 | • • • • • | ||||
A61K 9/64 | • • • • • containing proteins or derivatives thereof [2006.01] | ||||
A61K 9/66 | • • • containing emulsions, dispersions or solutions [2006.01] | ||||
D | A61K 9/68 | • chewing gum type [2006.01] | |||
D | A61K 9/70 | • Web, sheet or filament bases [2006.01] | |||
A61K 9/72 | • for smoking or inhaling [2006.01] | ||||
Note(s) [2006.01]
| |||||
A61K 31/00 | Medicinal preparations containing organic active ingredients [2006.01] | ||||
Note(s) [7]
| |||||
D | A61K 31/01 | • Hydrocarbons [2006.01] | |||
D | A61K 31/015 | • • carbocyclic [2006.01] | |||
D | A61K 31/02 | • Halogenated hydrocarbons [2006.01] | |||
Warning: Reclassification of PCT Minimum Documentation published before January 1, 2015, from group A61K 35/14 to this group is not yet completed! See also the Revision Concordance List (RCL) for more details. | |||||
D | A61K 31/025 | • • carbocyclic [2006.01] | |||
D | A61K 31/03 | • • • aromatic [2006.01] | |||
D | A61K 31/035 | • • having aliphatic unsaturation [2006.01] | |||
D | A61K 31/04 | • Nitro compounds [2006.01] | |||
D | A61K 31/045 | • Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates (hydroperoxides A61K 31/327) [2006.01] | |||
D | A61K 31/047 | • • having two or more hydroxy groups, e.g. sorbitol [2006.01] | |||
D | A61K 31/05 | • • Phenols [2006.01] | |||
D | A61K 31/055 | • • • the aromatic ring being substituted by halogen [2006.01] | |||
D | A61K 31/06 | • • • the aromatic ring being substituted by nitro groups [2006.01] | |||
D | A61K 31/065 | • • Diphenyl-substituted acyclic alcohols [2006.01] | |||
D | A61K 31/07 | • • Retinol compounds, e.g. vitamin A (retinoic acids A61K 31/203) [2006.01] | |||
D | A61K 31/075 | • Ethers or acetals [2006.01] | |||
D | A61K 31/08 | • • acyclic, e.g. paraformaldehyde [2006.01] | |||
D | A61K 31/085 | • • having an ether linkage to aromatic ring nuclear carbon [2006.01] | |||
D | A61K 31/09 | • • • having two or more such linkages [2006.01] | |||
D | A61K 31/095 | • Sulfur, selenium or tellurium compounds, e.g. thiols [2006.01] | |||
D | A61K 31/10 | • • Sulfides; Sulfoxides; Sulfones [2006.01] | |||
D | A61K 31/105 | • • Persulfides (thiuram disulfides A61K 31/145; thiosulfonic acids A61K 31/185) [2006.01] | |||
D | A61K 31/11 | • Aldehydes [2006.01] | |||
D | A61K 31/115 | • • Formaldehyde [2006.01] | |||
D | A61K 31/12 | • Ketones [2006.01] | |||
D | A61K 31/121 | • • acyclic [2006.01] | |||
D | A61K 31/122 | • • having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin [2006.01] | |||
D | A61K 31/125 | • • • Camphor; Nuclear substituted derivatives thereof [2006.01] | |||
D | A61K 31/13 | • Amines, e.g. amantadine (A61K 31/04 takes precedence) [2006.01] | |||
D | A61K 31/131 | • • acyclic [2006.01] | |||
D | A61K 31/132 | • • having two or more amino groups, e.g. spermidine, putrescine [2006.01] | |||
D | A61K 31/133 | • • having hydroxy groups, e.g. sphingosine [2006.01] | |||
D | A61K 31/135 | • • having aromatic rings, e.g. methadone [2006.01] | |||
D | A61K 31/136 | • • • having the amino group directly attached to the aromatic ring, e.g. benzeneamine [2006.01] | |||
D | A61K 31/137 | • • • Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine [2006.01] | |||
D | A61K 31/138 | • • • Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K 31/165; pindolol A61K 31/404; timolol A61K 31/5377) [2006.01] | |||
D | A61K 31/14 | • • Quaternary ammonium compounds, e.g. edrophonium, choline (betaines A61K 31/205) [2006.01] | |||
D | A61K 31/145 | • • having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N); Sulfinylamines (—N=SO); Sulfonylamines (—N=SO2) (isothioureas A61K 31/155) [2006.01] | |||
D | A61K 31/15 | • • Oximes (C=N—O—); Hydrazines (N—N); Hydrazones (N—N=) [2006.01] | |||
D | A61K 31/155 | • • Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2) [2006.01] | |||
D | A61K 31/16 | • Amides, e.g. hydroxamic acids [2006.01] | |||
D | A61K 31/164 | • • of a carboxylic acid with an aminoalcohol, e.g. ceramides [2006.01] | |||
D | A61K 31/165 | • • having aromatic rings, e.g. colchicine, atenolol, progabide [2006.01] | |||
D | A61K 31/166 | • • • having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol [2006.01] | |||
D | A61K 31/167 | • • • having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol [2006.01] | |||
D | A61K 31/17 | • • having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K 31/155; sulfonylureas A61K 31/64) [2006.01] | |||
D | A61K 31/175 | • • • having the group , N—C(O)—N=N— or , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof [2006.01] | |||
D | A61K 31/18 | • • Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N-group A61K 31/63) [2006.01] | |||
D | A61K 31/185 | • Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K 31/16; peroxy acids A61K 31/327) [2006.01] | |||
D | A61K 31/19 | • • Carboxylic acids, e.g. valproic acid (salicylic acid A61K 31/60) [2006.01] | |||
D | A61K 31/191 | • • • Acyclic acids having two or more hydroxy groups, e.g. gluconic acid [2006.01] | |||
D | A61K 31/192 | • • • having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid [2006.01] | |||
D | A61K 31/194 | • • • having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid [2006.01] | |||
D | A61K 31/195 | • • • having an amino group [2006.01] | |||
• • • Note(s) [7]
| |||||
D | A61K 31/196 | • • • • the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil [2006.01] | |||
D | A61K 31/197 | • • • • the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K 31/205) [2006.01] | |||
D | A61K 31/198 | • • • • • Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K 31/205; proline A61K 31/401; tryptophan A61K 31/405; histidine A61K 31/4172; peptides not degraded to individual amino acids A61K 38/00) [2006.01] | |||
D | A61K 31/20 | • • • having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid [2006.01] | |||
D | A61K 31/201 | • • • • having one or two double bonds, e.g. oleic or linoleic acid [2006.01] | |||
D | A61K 31/202 | • • • • having three or more double bonds, e.g. linolenic acid (eicosanoids, e.g. leukotrienes, A61K 31/557) [2006.01] | |||
D | A61K 31/203 | • • • • Retinoic acids [2006.01] | |||
D | A61K 31/205 | • • Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine [2006.01] | |||
D | A61K 31/21 | • Esters, e.g. nitroglycerine, selenocyanates [2006.01] | |||
D | A61K 31/215 | • • of carboxylic acids [2006.01] | |||
D | A61K 31/216 | • • • of acids having aromatic rings, e.g. benactizyne, clofibrate [2006.01] | |||
D | A61K 31/22 | • • • of acyclic acids, e.g. pravastatin [2006.01] | |||
D | A61K 31/221 | • • • • with compounds having an amino group, e.g. acetylcholine, acetylcarnitine [2006.01] | |||
D | A61K 31/222 | • • • • with compounds having aromatic groups, e.g. dipivefrine, ibopamine [2006.01] | |||
D | A61K 31/223 | • • • • of alpha-amino acids [2006.01] | |||
D | A61K 31/225 | • • • • Polycarboxylic acids [2006.01] | |||
D | A61K 31/23 | • • • • of acids having a carboxyl group bound to a chain of seven or more carbon atoms [2006.01] | |||
D | A61K 31/231 | • • • • • having one or two double bonds [2006.01] | |||
D | A61K 31/232 | • • • • • having three or more double bonds, e.g. etretinate [2006.01] | |||
D | A61K 31/235 | • • • having an aromatic ring attached to a carboxyl group [2006.01] | |||
D | A61K 31/24 | • • • • having an amino or nitro group [2006.01] | |||
D | A61K 31/245 | • • • • • Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K 31/60) [2006.01] | |||
D | A61K 31/25 | • • • with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol [2006.01] | |||
D | A61K 31/255 | • • of sulfoxy acids or sulfur analogues thereof [2006.01] | |||
D | A61K 31/26 | • • Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters [2006.01] | |||
D | A61K 31/265 | • • of carbonic, thiocarbonic or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid [2006.01] | |||
D | A61K 31/27 | • • of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine [2006.01] | |||
D | A61K 31/275 | • Nitriles; Isonitriles [2006.01] | |||
D | A61K 31/277 | • • having a ring, e.g. verapamil [2006.01] | |||
D | A61K 31/28 | • Compounds containing heavy metals [2006.01] | |||
D | A61K 31/282 | • • Platinum compounds [2006.01] | |||
D | A61K 31/285 | • • Arsenic compounds [2006.01] | |||
D | A61K 31/29 | • • Antimony or bismuth compounds [2006.01] | |||
D | A61K 31/295 | • • Iron group metal compounds [2006.01] | |||
D | A61K 31/30 | • • Copper compounds [2006.01] | |||
D | A61K 31/305 | • • Mercury compounds [2006.01] | |||
D | A61K 31/31 | • • • containing nitrogen [2006.01] | |||
D | A61K 31/315 | • • Zinc compounds [2006.01] | |||
D | A61K 31/32 | • • Tin compounds [2006.01] | |||
D | A61K 31/325 | • Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof (thiurams A61K 31/145) [2006.01] | |||
D | A61K 31/327 | • Peroxy compounds, e.g. hydroperoxides, peroxides, peroxy acids [2006.01] | |||
D | A61K 31/33 | • Heterocyclic compounds [2006.01] | |||
D | A61K 31/335 | • • having oxygen as the only ring hetero atom, e.g. fungichromin [2006.01] | |||
D | A61K 31/336 | • • • having three-membered rings, e.g. oxirane, fumagillin [2006.01] | |||
D | A61K 31/337 | • • • having four-membered rings, e.g. taxol [2006.01] | |||
D | A61K 31/34 | • • • having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide [2006.01] | |||
D | A61K 31/341 | • • • • not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine [2006.01] | |||
D | A61K 31/343 | • • • • condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone [2006.01] | |||
D | A61K 31/345 | • • • • Nitrofurans (nitrofurantoin A61K 31/4178) [2006.01] | |||
A61K 31/35 | • • • having six-membered rings with one oxygen as the only ring hetero atom [2006.01] | ||||
D | A61K 31/351 | • • • • not condensed with another ring [2006.01] | |||
D | A61K 31/352 | • • • • condensed with carbocyclic rings, e.g. cannabinols, methantheline [2006.01] | |||
D | A61K 31/353 | • • • • • 3,4-Dihydrobenzopyrans, e.g. chroman, catechin [2006.01] | |||
D | A61K 31/355 | • • • • • • Tocopherols, e.g. vitamin E [2006.01] | |||
D | A61K 31/357 | • • • having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel [2006.01] | |||
D | A61K 31/36 | • • • • Compounds containing methylenedioxyphenyl groups, e.g. sesamin [2006.01] | |||
A61K 31/365 | • • • Lactones [2006.01] | ||||
D | A61K 31/366 | • • • • having six-membered rings, e.g. delta-lactones [2006.01] | |||
D | A61K 31/37 | • • • • • Coumarins, e.g. psoralen [2006.01] | |||
D | A61K 31/375 | • • • • Ascorbic acid, i.e. vitamin C; Salts thereof [2006.01] | |||
D | A61K 31/38 | • • having sulfur as a ring hetero atom [2006.01] | |||
D | A61K 31/381 | • • • having five-membered rings [2006.01] | |||
D | A61K 31/382 | • • • having six-membered rings, e.g. thioxanthenes (thiothixene A61K 31/496) [2006.01] | |||
D | A61K 31/385 | • • • having two or more sulfur atoms in the same ring [2006.01] | |||
D | A61K 31/39 | • • • having oxygen atoms in the same ring [2006.01] | |||
D | A61K 31/395 | • • having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins [2006.01] | |||
D | A61K 31/396 | • • • having three-membered rings, e.g. aziridine [2006.01] | |||
D | A61K 31/397 | • • • having four-membered rings, e.g. azetidine [2006.01] | |||
D | A61K 31/40 | • • • having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil [2006.01] | |||
D | A61K 31/401 | • • • • Proline; Derivatives thereof, e.g. captopril [2006.01] | |||
D | A61K 31/4015 | • • • • having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide [2006.01] | |||
D | A61K 31/402 | • • • • 1-aryl-substituted, e.g. piretanide [2006.01] | |||
D | A61K 31/4025 | • • • • not condensed and containing further heterocyclic rings, e.g. cromakalim [2006.01] | |||
D | A61K 31/403 | • • • • condensed with carbocyclic rings, e.g. carbazole [2006.01] | |||
D | A61K 31/4035 | • • • • • Isoindoles, e.g. phthalimide [2006.01] | |||
D | A61K 31/404 | • • • • • Indoles, e.g. pindolol [2006.01] | |||
D | A61K 31/4045 | • • • • • • Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin [2006.01] | |||
D | A61K 31/405 | • • • • • • Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin [2006.01] | |||
D | A61K 31/407 | • • • • condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine [2006.01] | |||
D | A61K 31/409 | • • • • having four such rings, e.g. porphine derivatives, bilirubin, biliverdine (hemin, hematin A61K 31/555) [2006.01] | |||
D | A61K 31/41 | • • • having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole [2006.01] | |||
D | A61K 31/415 | • • • • 1,2-Diazoles [2006.01] | |||
D | A61K 31/4152 | • • • • • having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone [2006.01] | |||
D | A61K 31/4155 | • • • • • not condensed and containing further heterocyclic rings [2006.01] | |||
D | A61K 31/416 | • • • • • condensed with carbocyclic ring systems, e.g. indazole [2006.01] | |||
D | A61K 31/4162 | • • • • • condensed with heterocyclic ring systems [2006.01] | |||
D | A61K 31/4164 | • • • • 1,3-Diazoles [2006.01] | |||
D | A61K 31/4166 | • • • • • having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin [2006.01] | |||
D | A61K 31/4168 | • • • • • having a nitrogen atom attached in position 2, e.g. clonidine [2006.01] | |||
D | A61K 31/417 | • • • • • Imidazole-alkylamines, e.g. histamine, phentolamine [2006.01] | |||
D | A61K 31/4172 | • • • • • Imidazole-alkanecarboxylic acids, e.g. histidine [2006.01] | |||
D | A61K 31/4174 | • • • • • Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole [2006.01] | |||
D | A61K 31/4178 | • • • • • not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin [2006.01] | |||
D | A61K 31/4184 | • • • • • condensed with carbocyclic rings, e.g. benzimidazoles [2006.01] | |||
D | A61K 31/4188 | • • • • • condensed with heterocyclic ring systems, e.g. biotin, sorbinil [2006.01] | |||
D | A61K 31/4192 | • • • • 1,2,3-Triazoles [2006.01] | |||
D | A61K 31/4196 | • • • • 1,2,4-Triazoles [2006.01] | |||
D | A61K 31/42 | • • • • Oxazoles [2006.01] | |||
D | A61K 31/421 | • • • • • 1,3-Oxazoles, e.g. pemoline, trimethadione [2006.01] | |||
D | A61K 31/422 | • • • • • not condensed and containing further heterocyclic rings [2006.01] | |||
D | A61K 31/423 | • • • • • condensed with carbocyclic rings [2006.01] | |||
D | A61K 31/424 | • • • • • condensed with heterocyclic ring systems, e.g. clavulanic acid [2006.01] | |||
D | A61K 31/4245 | • • • • Oxadiazoles [2006.01] | |||
D | A61K 31/425 | • • • • Thiazoles [2006.01] | |||
D | A61K 31/426 | • • • • • 1,3-Thiazoles [2006.01] | |||
D | A61K 31/427 | • • • • • not condensed and containing further heterocyclic rings [2006.01] | |||
D | A61K 31/428 | • • • • • condensed with carbocyclic rings [2006.01] | |||
D | A61K 31/429 | • • • • • condensed with heterocyclic ring systems [2006.01] | |||
D | A61K 31/43 | • • • • • • Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems [2006.01] | |||
D | A61K 31/431 | • • • • • • • containing further heterocyclic ring systems, e.g. ticarcillin, azlocillin, oxacillin [2006.01] | |||
D | A61K 31/433 | • • • • Thiadiazoles [2006.01] | |||
D | A61K 31/435 | • • • having six-membered rings with one nitrogen as the only ring hetero atom [2006.01] | |||
D | A61K 31/4353 | • • • • ortho- or peri-condensed with heterocyclic ring systems [2006.01] | |||
D | A61K 31/4355 | • • • • • the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom [2006.01] | |||
D | A61K 31/436 | • • • • • the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin [2006.01] | |||
D | A61K 31/4365 | • • • • • the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine [2006.01] | |||
D | A61K 31/437 | • • • • • the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline [2006.01] | |||
D | A61K 31/4375 | • • • • • the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine [2006.01] | |||
D | A61K 31/438 | • • • • the ring being spiro-condensed with carbocyclic or heterocyclic ring systems [2006.01] | |||
D | A61K 31/439 | • • • • the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K 31/46) [2006.01] | |||
D | A61K 31/44 | • • • • Non-condensed pyridines; Hydrogenated derivatives thereof [2006.01] | |||
D | A61K 31/4402 | • • • • • only substituted in position 2, e.g. pheniramine, bisacodyl [2006.01] | |||
D | A61K 31/4406 | • • • • • only substituted in position 3, e.g. zimeldine (nicotinic acid A61K 31/455) [2006.01] | |||
D | A61K 31/4409 | • • • • • only substituted in position 4, e.g. isoniazid, iproniazid [2006.01] | |||
D | A61K 31/4412 | • • • • • having oxo groups directly attached to the heterocyclic ring [2006.01] | |||
D | A61K 31/4415 | • • • • • Pyridoxine, i.e.vitamin B6 (pyridoxal phosphate A61K 31/675) [2006.01] | |||
D | A61K 31/4418 | • • • • • having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine [2006.01] | |||
D | A61K 31/4422 | • • • • • 1,4-Dihydropyridines, e.g. nifedipine, nicardipine [2006.01] | |||
D | A61K 31/4425 | • • • • • Pyridinium derivatives, e.g. pralidoxime, pyridostigmine [2006.01] | |||
D | A61K 31/4427 | • • • • • containing further heterocyclic ring systems [2006.01] | |||
D | A61K 31/443 | • • • • • • containing a five-membered ring with oxygen as a ring hetero atom [2006.01] | |||
D | A61K 31/4433 | • • • • • • containing a six-membered ring with oxygen as a ring hetero atom [2006.01] | |||
D | A61K 31/4436 | • • • • • • containing a heterocyclic ring having sulfur as a ring hetero atom [2006.01] | |||
D | A61K 31/4439 | • • • • • • containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K 31/465) [2006.01] | |||
D | A61K 31/444 | • • • • • • containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone [2006.01] | |||
D | A61K 31/445 | • • • • • Non-condensed piperidines, e.g. piperocaine [2006.01] | |||
D | A61K 31/4453 | • • • • • • only substituted in position 1, e.g. propipocaine, diperodon [2006.01] | |||
D | A61K 31/4458 | • • • • • • only substituted in position 2, e.g. methylphenidate [2006.01] | |||
D | A61K 31/4462 | • • • • • • only substituted in position 3 [2006.01] | |||
D | A61K 31/4465 | • • • • • • only substituted in position 4 [2006.01] | |||
D | A61K 31/4468 | • • • • • • having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl [2006.01] | |||
D | A61K 31/45 | • • • • • • having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide [2006.01] | |||
D | A61K 31/451 | • • • • • • having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine [2006.01] | |||
D | A61K 31/4515 | • • • • • • having a butyrophenone group in position 1, e.g. haloperidol (pipamperone A61K 31/4545) [2006.01] | |||
D | A61K 31/452 | • • • • • • Piperidinium derivatives (pancuronium A61K 31/58) [2006.01] | |||
D | A61K 31/4523 | • • • • • • containing further heterocyclic ring systems [2006.01] | |||
D | A61K 31/4525 | • • • • • • • containing a five-membered ring with oxygen as a ring hetero atom [2006.01] | |||
D | A61K 31/453 | • • • • • • • containing a six-membered ring with oxygen as a ring hetero atom [2006.01] | |||
D | A61K 31/4535 | • • • • • • • containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen [2006.01] | |||
A61K 31/454 | • • • • • • • containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone [2006.01] | ||||
D | A61K 31/4545 | • • • • • • • containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine [2006.01] | |||
D | A61K 31/455 | • • • • • Nicotinic acid, i.e. niacin; Derivatives thereof, e.g. esters, amides [2006.01] | |||
D | A61K 31/46 | • • • • 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine [2006.01] | |||
D | A61K 31/465 | • • • • Nicotine; Derivatives thereof [2006.01] | |||
D | A61K 31/47 | • • • • Quinolines; Isoquinolines [2006.01] | |||
D | A61K 31/4704 | • • • • • 2-Quinolinones, e.g. carbostyril [2006.01] | |||
D | A61K 31/4706 | • • • • • 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine [2006.01] | |||
D | A61K 31/4709 | • • • • • Non-condensed quinolines containing further heterocyclic rings [2006.01] | |||
D | A61K 31/472 | • • • • • Non-condensed isoquinolines, e.g. papaverine [2006.01] | |||
D | A61K 31/4725 | • • • • • • containing further heterocyclic rings [2006.01] | |||
D | A61K 31/473 | • • • • • ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines [2006.01] | |||
D | A61K 31/4738 | • • • • • ortho- or peri-condensed with heterocyclic ring systems [2006.01] | |||
D | A61K 31/4741 | • • • • • • condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline [2006.01] | |||
D | A61K 31/4743 | • • • • • • condensed with ring systems having sulfur as a ring hetero atom [2006.01] | |||
D | A61K 31/4745 | • • • • • • condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines (yohimbine derivatives, vinblastine A61K 31/475; ergoline derivatives A61K 31/48) [2006.01] | |||
D | A61K 31/4747 | • • • • • spiro-condensed [2006.01] | |||
D | A61K 31/4748 | • • • • • forming part of bridged ring systems (strychnine A61K 31/475; morphinan derivatives A61K 31/485) [2006.01] | |||
D | A61K 31/475 | • • • • • having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K 31/4375) [2006.01] | |||
D | A61K 31/48 | • • • • • Ergoline derivatives, e.g. lysergic acid, ergotamine [2006.01] | |||
D | A61K 31/485 | • • • • • Morphinan derivatives, e.g. morphine, codeine [2006.01] | |||
D | A61K 31/49 | • • • • • Cinchonan derivatives, e.g. quinine [2006.01] | |||
D | A61K 31/495 | • • • having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine (A61K 31/48 takes precedence) [2006.01] | |||
D | A61K 31/496 | • • • • Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin [2006.01] | |||
D | A61K 31/4965 | • • • • Non-condensed pyrazines [2006.01] | |||
D | A61K 31/497 | • • • • • containing further heterocyclic rings [2006.01] | |||
D | A61K 31/498 | • • • • Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine [2006.01] | |||
D | A61K 31/4985 | • • • • Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems [2006.01] | |||
D | A61K 31/499 | • • • • Spiro-condensed pyrazines or piperazines [2006.01] | |||
D | A61K 31/4995 | • • • • Pyrazines or piperazines forming part of bridged ring systems [2006.01] | |||
D | A61K 31/50 | • • • • Pyridazines; Hydrogenated pyridazines [2006.01] | |||
D | A61K 31/501 | • • • • • not condensed and containing further heterocyclic rings [2006.01] | |||
D | A61K 31/502 | • • • • • ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine [2006.01] | |||
D | A61K 31/5025 | • • • • • ortho- or peri-condensed with heterocyclic ring systems [2006.01] | |||
D | A61K 31/503 | • • • • • spiro-condensed [2006.01] | |||
D | A61K 31/504 | • • • • • forming part of bridged ring systems [2006.01] | |||
D | A61K 31/505 | • • • • Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim [2006.01] | |||
D | A61K 31/506 | • • • • • not condensed and containing further heterocyclic rings [2006.01] | |||
D | A61K 31/51 | • • • • • • Thiamines, e.g. vitamin B1 [2006.01] | |||
D | A61K 31/513 | • • • • • having oxo groups directly attached to the heterocyclic ring, e.g. cytosine [2006.01] | |||
D | A61K 31/515 | • • • • • • Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital [2006.01] | |||
D | A61K 31/517 | • • • • • ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine [2006.01] | |||
D | A61K 31/519 | • • • • • ortho- or peri-condensed with heterocyclic rings [2006.01] | |||
D | A61K 31/52 | • • • • • • Purines, e.g. adenine [2006.01] | |||
D | A61K 31/522 | • • • • • • • having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir [2006.01] | |||
D | A61K 31/525 | • • • • • • Isoalloxazines, e.g. riboflavins, vitamin B2 [2006.01] | |||
D | A61K 31/527 | • • • • • spiro-condensed [2006.01] | |||
D | A61K 31/529 | • • • • • forming part of bridged ring systems [2006.01] | |||
D | A61K 31/53 | • • • having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K 31/555) [2006.01] | |||
D | A61K 31/535 | • • • having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines [2006.01] | |||
D | A61K 31/5355 | • • • • Non-condensed oxazines containing further heterocyclic rings [2006.01] | |||
D | A61K 31/536 | • • • • ortho- or peri-condensed with carbocyclic ring systems [2006.01] | |||
D | A61K 31/5365 | • • • • ortho- or peri-condensed with heterocyclic ring systems [2006.01] | |||
D | A61K 31/537 | • • • • spiro-condensed or forming part of bridged ring systems [2006.01] | |||
D | A61K 31/5375 | • • • • 1,4-Oxazines, e.g. morpholine [2006.01] | |||
D | A61K 31/5377 | • • • • • not condensed and containing further heterocyclic rings, e.g. timolol [2006.01] | |||
D | A61K 31/538 | • • • • • ortho- or peri-condensed with carbocyclic ring systems [2006.01] | |||
D | A61K 31/5383 | • • • • • ortho- or peri-condensed with heterocyclic ring systems [2006.01] | |||
D | A61K 31/5386 | • • • • • spiro-condensed or forming part of bridged ring systems [2006.01] | |||
D | A61K 31/539 | • • • • having two or more oxygen atoms in the same ring, e.g dioxazines [2006.01] | |||
D | A61K 31/5395 | • • • • having two or more nitrogen atoms in the same ring, e.g. oxadiazines [2006.01] | |||
D | A61K 31/54 | • • • having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame [2006.01] | |||
D | A61K 31/541 | • • • • Non-condensed thiazines containing further heterocyclic rings [2006.01] | |||
D | A61K 31/5415 | • • • • ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam [2006.01] | |||
D | A61K 31/542 | • • • • ortho- or peri-condensed with heterocyclic ring systems [2006.01] | |||
D | A61K 31/545 | • • • • • Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine [2006.01] | |||
D | A61K 31/546 | • • • • • • containing further heterocyclic rings, e.g. cephalothin [2006.01] | |||
D | A61K 31/547 | • • • • spiro-condensed or forming part of bridged ring systems [2006.01] | |||
D | A61K 31/548 | • • • • having two or more sulfur atoms in the same ring [2006.01] | |||
D | A61K 31/549 | • • • • having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide [2006.01] | |||
D | A61K 31/55 | • • • having seven-membered rings, e.g. azelastine, pentylenetetrazole [2006.01] | |||
D | A61K 31/551 | • • • • having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep [2006.01] | |||
D | A61K 31/5513 | • • • • • 1,4-Benzodiazepines, e.g. diazepam [2006.01] | |||
D | A61K 31/5517 | • • • • • • condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam [2006.01] | |||
D | A61K 31/553 | • • • • having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine [2006.01] | |||
D | A61K 31/554 | • • • • having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem [2006.01] | |||
D | A61K 31/555 | • • containing heavy metals, e.g. hemin, hematin, melarsoprol [2006.01] | |||
D | A61K 31/557 | • Eicosanoids, e.g. leukotrienes [2006.01] | |||
D | A61K 31/5575 | • • having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha [2006.01] | |||
D | A61K 31/5578 | • • having a pentalene ring system, e.g. carbacyclin, iloprost [2006.01] | |||
D | A61K 31/558 | • • having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes [2006.01] | |||
A61K 31/5585 | • • • having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin [2006.01] | ||||
D | A61K 31/559 | • • having heterocyclic rings containing hetero atoms other than oxygen [2006.01] | |||
D | A61K 31/56 | • Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids [2006.01] | |||
• Note(s) [7]
| |||||
D | A61K 31/565 | • • not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol [2006.01] | |||
D | A61K 31/566 | • • • having an oxo group in position 17, e.g. oestrone [2006.01] | |||
D | A61K 31/567 | • • • substituted in position 17 alpha, e.g. mestranol, norethandrolone [2006.01] | |||
D | A61K 31/568 | • • • substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone [2006.01] | |||
D | A61K 31/5685 | • • • • having an oxo group in position 17, e.g. androsterone [2006.01] | |||
D | A61K 31/569 | • • • • substituted in position 17 alpha, e.g. ethisterone [2006.01] | |||
D | A61K 31/57 | • • substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone [2006.01] | |||
D | A61K 31/573 | • • • substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone [2006.01] | |||
D | A61K 31/575 | • • substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol [2006.01] | |||
D | A61K 31/58 | • • containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin A61K 31/704) [2006.01] | |||
D | A61K 31/585 | • • • containing lactone rings, e.g. oxandrolone, bufalin [2006.01] | |||
D | A61K 31/59 | • Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems [2006.01] | |||
D | A61K 31/592 | • • 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2 [2006.01] | |||
D | A61K 31/593 | • • 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3 [2006.01] | |||
D | A61K 31/60 | • Salicylic acid; Derivatives thereof [2006.01] | |||
D | A61K 31/603 | • • having further aromatic rings, e.g. diflunisal [2006.01] | |||
D | A61K 31/606 | • • having amino groups [2006.01] | |||
D | A61K 31/609 | • • Amides, e.g. salicylamide [2006.01] | |||
D | A61K 31/612 | • • having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid (fosfosal A61K 31/661) [2006.01] | |||
D | A61K 31/616 | • • • by carboxylic acids, e.g. acetylsalicylic acid [2006.01] | |||
D | A61K 31/618 | • • having the carboxyl group in position 1 esterified, e.g. salsalate [2006.01] | |||
D | A61K 31/621 | • • • having the hydroxy group in position 2 esterified, e.g. benorylate [2006.01] | |||
D | A61K 31/625 | • • having heterocyclic substituents, e.g. 4-salicyloylmorpholine (sulfasalazine A61K 31/635) [2006.01] | |||
D | A61K 31/63 | • Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide [2006.01] | |||
D | A61K 31/635 | • • having a heterocyclic ring, e.g. sulfadiazine [2006.01] | |||
D | A61K 31/64 | • Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide [2006.01] | |||
D | A61K 31/65 | • Tetracyclines [2006.01] | |||
A61K 31/655 | • Azo (—N=N—), diazo (=N2), azoxy (N—O—N or N(=O)—N), azido (—N3) or diazoamino (—N=N—N) compounds [2006.01] | ||||
D | A61K 31/66 | • Phosphorus compounds [2006.01] | |||
D | A61K 31/661 | • • Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion [2006.01] | |||
A61K 31/6615 | • • • Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid [2006.01] | ||||
A61K 31/662 | • • Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon [2006.01] | ||||
A61K 31/663 | • • • Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid [2006.01] | ||||
A61K 31/664 | • • Amides of phosphorus acids [2006.01] | ||||
D | A61K 31/665 | • • having oxygen as a ring hetero atom, e.g. fosfomycin [2006.01] | |||
D | A61K 31/67 | • • having sulfur as a ring hetero atom [2006.01] | |||
D | A61K 31/675 | • • having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate [2006.01] | |||
A61K 31/683 | • • Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols [2006.01] | ||||
D | A61K 31/685 | • • • one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin [2006.01] | |||
A61K 31/688 | • • • both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins [2006.01] | ||||
A61K 31/69 | • Boron compounds [2006.01] | ||||
A61K 31/695 | • Silicon compounds [2006.01] | ||||
A61K 31/70 | • Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K 31/047) [2006.01] | ||||
• Note(s) [7]
| |||||
D | A61K 31/7004 | • • Monosaccharides having only carbon, hydrogen and oxygen atoms [2006.01] | |||
D | A61K 31/7008 | • • Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine [2006.01] | |||
D | A61K 31/7012 | • • Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid (gluconic acid A61K 31/191; ascorbic acid A61K 31/375) [2006.01] | |||
D | A61K 31/7016 | • • Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K 31/7032) [2006.01] | |||
D | A61K 31/702 | • • Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages [2006.01] | |||
D | A61K 31/7024 | • • Esters of saccharides [2006.01] | |||
D | A61K 31/7028 | • • Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages [2006.01] | |||
D | A61K 31/7032 | • • • attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides [2006.01] | |||
D | A61K 31/7034 | • • • attached to a carbocyclic compound, e.g. phloridzin [2006.01] | |||
D | A61K 31/7036 | • • • • having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins [2006.01] | |||
D | A61K 31/704 | • • • • attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin [2006.01] | |||
A61K 31/7042 | • • Compounds having saccharide radicals and heterocyclic rings [2006.01] | ||||
D | A61K 31/7048 | • • • having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin [2006.01] | |||
A61K 31/7052 | • • • having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides [2006.01] | ||||
D | A61K 31/7056 | • • • • containing five-membered rings with nitrogen as a ring hetero atom [2006.01] | |||
D | A61K 31/706 | • • • • containing six-membered rings with nitrogen as a ring hetero atom [2006.01] | |||
D | A61K 31/7064 | • • • • • containing condensed or non-condensed pyrimidines [2006.01] | |||
D | A61K 31/7068 | • • • • • • having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid [2006.01] | |||
D | A61K 31/7072 | • • • • • • • having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine [2006.01] | |||
D | A61K 31/7076 | • • • • • • containing purines, e.g. adenosine, adenylic acid [2006.01] | |||
D | A61K 31/708 | • • • • • • • having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid [2006.01] | |||
D | A61K 31/7084 | • • Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide [2006.01] | |||
A61K 31/7088 | • • Compounds having three or more nucleosides or nucleotides [2006.01] | ||||
D | A61K 31/7105 | • • • Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links [2006.01] | |||
D | A61K 31/711 | • • • Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links [2006.01] | |||
D | A61K 31/7115 | • • • Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine [2006.01] | |||
A61K 31/712 | • • • Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose [2006.01] | ||||
A61K 31/7125 | • • • Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters [2006.01] | ||||
A61K 31/713 | • • • Double-stranded nucleic acids or oligonucleotides [2006.01] | ||||
A61K 31/7135 | • • Compounds containing heavy metals [2006.01] | ||||
D | A61K 31/714 | • • • Cobalamins, e.g. cyanocobalamin, vitamin B12 [2006.01] | |||
D | A61K 31/715 | • • Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters [2006.01] | |||
A61K 31/716 | • • • Glucans [2006.01] | ||||
D | A61K 31/717 | • • • • Celluloses [2006.01] | |||
A61K 31/718 | • • • • Starch or degraded starch, e.g. amylose, amylopectin [2006.01] | ||||
A61K 31/719 | • • • • Pullulans [2006.01] | ||||
A61K 31/721 | • • • • Dextrans [2006.01] | ||||
A61K 31/722 | • • • • Chitin; Chitosan [2006.01] | ||||
A61K 31/723 | • • • • Xanthans [2006.01] | ||||
A61K 31/724 | • • • • Cyclodextrins [2006.01] | ||||
A61K 31/726 | • • • Glycosaminoglycans, i.e. mucopolysaccharides (chondroitin sulfate, dermatan sulfate A61K 31/737) [2006.01] | ||||
A61K 31/727 | • • • • Heparin; Heparan [2006.01] | ||||
A61K 31/728 | • • • • Hyaluronic acid [2006.01] | ||||
A61K 31/729 | • • • Agar; Agarose; Agaropectin [2006.01] | ||||
A61K 31/731 | • • • Carrageenans [2006.01] | ||||
A61K 31/732 | • • • Pectin [2006.01] | ||||
A61K 31/733 | • • • Fructosans, e.g. inulin [2006.01] | ||||
A61K 31/734 | • • • Alginic acid [2006.01] | ||||
A61K 31/736 | • • • Glucomannans or galactomannans, e.g locust bean gum, guar gum [2006.01] | ||||
A61K 31/737 | • • • Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K 31/727 takes precedence) [2006.01] | ||||
A61K 31/738 | • • • Cross-linked polysaccharides [2006.01] | ||||
A61K 31/739 | • • • Lipopolysaccharides [2006.01] | ||||
A61K 31/74 | • | ||||
D | A61K 31/745 | • • Polymers of hydrocarbons [2006.01] | |||
D | A61K 31/75 | • • • of ethene [2006.01] | |||
D | A61K 31/755 | • • Polymers containing halogen [2006.01] | |||
D | A61K 31/76 | • • • of vinyl chloride [2006.01] | |||
A61K 31/765 | • • Polymers containing oxygen [2006.01] | ||||
D | A61K 31/77 | • • • of oxiranes [2006.01] | |||
A61K 31/775 | • • • Phenolic resins [2006.01] | ||||
A61K 31/78 | • • • of acrylic acid or derivatives thereof [2006.01] | ||||
A61K 31/785 | • • Polymers containing nitrogen [2006.01] | ||||
A61K 31/787 | • • • containing heterocyclic rings having nitrogen as a ring hetero atom [2006.01] | ||||
A61K 31/79 | • • • • Polymers of vinyl pyrrolidone [2006.01] | ||||
A61K 31/795 | • • Polymers containing sulfur [2006.01] | ||||
A61K 31/80 | • • | ||||
A61K 33/00 | Medicinal preparations containing inorganic active ingredients [2006.01] | ||||
A61K 35/00 | Medicinal preparations containing materials or reaction products thereof with undetermined constitution [2006.01] | ||||
A61K 36/00 | Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines [2006.01] | ||||
A61K 38/00 | Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K 31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K 31/00; ergoline-based peptides A61K 31/48; containing macromolecular compounds having statistically distributed amino acid units A61K 31/74; medicinal preparations containing antigens or antibodies A61K 39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K 47/00) [2006.01] | ||||
A61K 39/00 | Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N 33/53) [2006.01] | ||||
D | A61K 40/00 | Cellular immunotherapy (medicinal preparations containing antigens or antibodies A61K 39/00) [2025.01] | |||
D | A61K 41/00 | Medicinal preparations obtained by treating materials with wave energy or particle radiation [2020.01] | |||
A61K 45/00 | Medicinal preparations containing active ingredients not provided for in groups A61K 31/00-A61K 41/00 [2006.01] | ||||
D | A61K 47/00 | Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient [2006.01] | |||
A61K 48/00 | Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy [2006.01] | ||||
A61K 49/00 | Preparations for testing in vivo [2006.01] | ||||
D | A61K 50/00 | Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography [ECG] or for transcutaneous drug administration [2006.01] | |||
A61K 51/00 | |||||
Indexing scheme associated with group A61K 51/00, relating to the nature of the radioactive substance. [6] | |||||
A61K 101/00 | Radioactive non-metals [2006.01] | ||||
A61K 103/00 | Radioactive metals [2006.01] | ||||
Indexing scheme associated with group A61K 36/00, relating to plant parts with medicinal activity. [2006.01] | |||||
A61K 125/00 | Containing or obtained from roots, bulbs, tubers, corms or rhizomes [2006.01] | ||||
A61K 127/00 | Containing or obtained from leaves [2006.01] | ||||
A61K 129/00 | Containing or obtained from bark [2006.01] | ||||
A61K 131/00 | Containing or obtained from seeds, nuts, fruits or grains [2006.01] | ||||
A61K 133/00 | Containing or obtained from flowers or blossoms [2006.01] | ||||
A61K 135/00 | Containing or obtained from stems, stalks, branches, twigs or shoots [2006.01] | ||||